Effects of Dapagliflozin on EChOcardiographic Measures of CarDiac StructurE and Function in Patients with CKD

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 222 participants.

Also called NCT05359263

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 222 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05359263
Other papers using this trial's data
  • Cardiac Effects of Dapagliflozin in People with Chronic Kidney Disease NEJM evidence, 2025-11 DOI, PubMed 41147829

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Denmark (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT05359263. Randomized; triple masking; primary purpose treatment. Start 2022-06-08 (actual); primary completion 2025-02-18 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effects of Dapagliflozin on EChOcardiographic Measures of CarDiac StructurE and Function in Patients with CKD
Acronym
DECODE-CKD
Condition
Chronic Kidney Diseases
Intervention (Drug)
Dapagliflozin 10 mg
Intervention (Drug)
Placebo
Lead sponsor
Tor Biering-Sørensen (class: other)

Record details

Record id
cardio:ct-nct05359263
Content hash
d1e7e20eedae5596fd322117c37d5389adf8f5469051f74a873b115000440917